Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Patients who receive a chemotherapy called melphalan are at high risk of having nausea and vomiting. A medication called olanzapine has been shown to decrease nausea and vomiting after chemotherapy. A previous research study found the 10 mg dose of olanzapine (combined with 3 standard medications used routinely to prevent nausea/vomiting) to be effective for patients who received melphalan chemotherapy, but several other studies have shown many patients have a side effect of sleepiness (e.g., sedation) with that dose of the medication. Our study will compare two lower doses of olanzapine (5 mg and 2.5 mg) in combination with the 3 standard medications used to prevent nausea/vomiting in the patients who receive melphalan chemotherapy to determine which dose is effective in preventing nausea and vomiting with the lowest amount of sleepiness side effect.
Sponsor: Augusta University
You may qualify if…
- ✓ Receipt of high-dose melphalan 140-200 mg/m2
- ✓ Autologous stem cell transplantation recipient
You may not qualify if…
- ✕ Allergy to olanzapine
- ✕ Documented nausea or vomiting within 24 hours prior to enrollment
- ✕ Treatment with other antipsychotic agents such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone within 30 days prior to enrollment or planned during protocol therapy
- ✕ Chronic alcoholism
- ✕ Pregnant
- ✕ Decline or unable to provide informed consent
Where it's recruiting
Augusta
Source: ClinicalTrials.gov · NCT06588413 · last updated 2024-11-22